Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Phase 4 Completed 144 enrolled Novartis

Non-randomizedFactorialOpen-labelTreatment

Summary

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

Timeline

Start: 2005-07
Primary completion: 2007-03
Completion: 2007-03

Publications

Results Ambrosioni E, Cicero AF, Parretti D, Filippi A, Rossi A, Peruzzi E, Borghi C. Global cardiovascular disease risk management in italian patients with metabolic syndrome in the clinical practice setting. High Blood Press Cardiovasc Prev. 2008 Apr;15(2):37-45. doi: 10.2165/00151642-200815020-00001. Epub 2013 Jan 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fluvastatin	Other / unclassified	80 mg	Oral
Subject	Hydrochlorothiazide	Unknown	12.5 mg	Oral
Subject	Valsartan	Small molecule	160 mg	Oral

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Summary

Timeline

Publications

Drugs

Indications